Clinical trials: Diabetes Mellitus Poor Control
Diabetes Mellitus, Type 2
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.
- Trial name
- NCT00468039
- Testing
- vildagliptin + metformin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus - Poor Control
A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients with Type 2 Diabetes…
- Trial name
- NCT07057271
- Testing
- CJC-1134-PC Injection
- Where
- China
- Volunteers
- 464 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Type 1 Diabetes
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive…
- Trial name
- RTD (NCT00441129)
- Testing
- Minimed paradigm Real Time Sytem, Minimed Paradigm 512/712 Insulin pump
- Where
- 8 sites in France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in…
- Trial name
- NCT00814372
- Testing
- MBX-102, Actos, Metformin
- Where
- 26 sites in United States, India
- Volunteers
- 242 people
- Sponsor
- Gilead Sciences
Type 1 Diabetes Mellitus
Effectiveness Study of the Guardian RT in Type 1 Diabetics
The purpose of this study is to determine whether Type 1 diabetic patients using the Guardian RT glucose sensor can improve glycemic control over a 12-week period, compared to patients using self-monitoring blood glucose testing…
- Trial name
- NCT01331343
- Testing
- Guardian RT Telemetered Glucose Monitoring System
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 156 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.
- Trial name
- NCT06339086
- Testing
- Semaglutide Injection, Semaglutide Injection(Ozempic®), Metformin
- Volunteers
- 478 people
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
Diabetes Mellitus
The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT
The objective of the study is to determine whether patients with poor glycemic control can improve metabolic control using the real-time values of the Guardian® RT compared to conventional self-monitoring blood glucose…
- Trial name
- NCT00111228
- Testing
- Guardian RT, SMBG only
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 162 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient…
- Trial name
- NCT05318326
- Testing
- Yogliptin 400mg group, Yogliptin 200mg group
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
Type 2 Diabetes
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
Retagliptin phosphate tablet is a DPP IV inhibitor durg，study number is HR-SP2086-304. The primary purpose of the study is to evaluate the efficacy of the combination of Retagliptin phosphate and metformin compared with placebo…
- Trial name
- NCT05054842
- Testing
- Retagliptin phosphate tablets、metformin sustained-release tablets
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
This trial is aimed to investigate the safety, tolerability, PK and PD of multiple subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor glycemic control after lifestyle or metformin intervention
- Trial name
- NCT04466904
- Testing
- IBI362, Dulaglutide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes Mellitus - Poor Control
A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once Weekly in Antidiabetic Treatment-naive Patients…
- Trial name
- NCT07058545
- Testing
- CJC-1134-PC Injection
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Type 2 Diabetes Mellitus - Poor Control
Continuous Glucose Monitoring, Diabetes Education, and Peer Support for Management of Uncontrolled Type 2 Diabetes
This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes.
- Trial name
- COMPASS (NCT07054125)
- Testing
- Education, lifestyle counseling, and peer support
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Whole Endo
Type 2 Diabetes Mellitus (T2DM)
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
- Trial name
- Optimum 1 (NCT06777238)
- Testing
- GZR18
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Type 2 Diabetes Mellitus
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.
- Trial name
- NCT02049814
- Testing
- Metformin, Voglibose, Acarbose
- Where
- 18 sites in China
- Volunteers
- 494 people
- Sponsor
- Takeda
Type 2 Diabetes
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.
- Trial name
- NCT06649773
- Testing
- Noiiglutide Injection
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the effectiveness and safety of IBI362 in patients with type 2 diabetes (T2D) with poor glycemia control only through diet…
- Trial name
- NCT05628311
- Testing
- IBI362
- Where
- China
- Volunteers
- 319 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
- Trial name
- MESSAGE (NCT07244003)
- Testing
- Metformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2, Diabetes
Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients
The goal of this investigator-initiated clinical trial is to investigate the efficacy and safety of sequential therapy of Fuling Yunhua Granules (prescription A) and Dihuang Baoyuan Granule (prescription B) in the treatment of…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes, Type2diabetes
- Trial name
- NCT06575478
- Testing
- Fuling Yunhua Granules, Dihuang Baoyuan Granules
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
- Trial name
- SYMPHONY-1 (NCT06350890)
- Testing
- HTD1801
- Where
- 56 sites in China
- Volunteers
- 408 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Diabetes Melliuts, Type 2
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
- Trial name
- NCT01673178
- Testing
- 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023
- Where
- 17 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer